期刊文献+

我院万古霉素临床联合用药合理性分析 被引量:3

Analysis on Rationality of Vancomycin Combination Use in Our Hospital
下载PDF
导出
摘要 目的评价医院万古霉素临床联合用药情况。方法参照卫生部颁布的《抗菌药物临床应用指导原则》,对2009年8月至2009年10月共123例使用万古霉素联合其他抗生素行药物治疗的住院患者进行临床资料的统计分析。结果万古霉素联合其他抗生素使用的比例为46.07%。结论万古霉素的使用基本符合有关规定,但还存在部分不合理用药现象,应根据临床适应证有针对性地用药,严格控制联合用药。 Objective To evaluate the status of vancomycin combination use in our hospital.Methods The medical records of 123 cases treated by vancomycin combination use during August to October in 2009 were collected and retrospectively analyzed based on the Guiding Principles for Clinical Application of Antibacterials issued by the Ministry of Health.Results The ratio of vancomycin combination wais 46.07%.Conclusion The use of vancomycin basically meets the standard,but there is still the phenomenon of irrational use.The use of vancomycin should be based on clinical indications,and the combination should be strictly controlled.
出处 《中国药业》 CAS 2011年第5期57-58,共2页 China Pharmaceuticals
关键词 万古霉素 联合用药 合理性分析 vancomycin combined medication rationality analysis
  • 相关文献

参考文献3

  • 1戴林.药物临床信息参考[M].成都:四川科学技术出版社,2007:667,1191-1193
  • 2Taggart T,Kerry RM,Narman P,et al.The use of vancomycin-impregnatcd cement beads in the management of infection of prosthetic joints[J].J Bone Joint Surg(Br),2002,84(1):70-72.
  • 3张婴元.革兰阳性球菌感染抗菌治疗进展[J].中国抗感染化疗杂志,2001,1(1):50-53. 被引量:25

二级参考文献37

  • 1Edmond M B, Wallace S E, MacClish D K, et al. Nosocomial Bloodstream infection in United States hospitals: a three-year analysis[J]. Clin Infect Dis, 1999, 29: 239-244.
  • 2Moellering R C. Problems with antimicrobial resistance in gram-positive cocci[J]. Clin Infect Dis 1998, 26: 1177-1178.
  • 3Fraise A P. Guidelines for the control of methicillin-resistant Staphylococcus aureus[J]. J Antimicrob Chemother, 1998, 42: 289-291.
  • 4Moellering R C. Vancomycin-resistant enterococci[J]. Clin Infect Dis, 1998, 26: 1196-1199.
  • 5Doern G V, Brueggemann A B, Huynh H, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98[J]. Emerg Infect Dis, 1999, 5: 757-765.
  • 6Song J H, Lee N Y, Ichiyama S. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian network for suveillance of resistant pathogens (ANSORP) study[J]. Clin Infect Dis 1999, 28:1206-1211.
  • 7Smith T L, Pearson M L, Wilcox K R, et al. Emergence of vancomycin resistnace in Staphylococcus aureus[J]. N E J Med 1999, 340: 493-501.
  • 8Bouanchaud D H. In vitro and in vivo antibacterial activity of quinupristin/dalfopristin[J]. J Antimicrob Chemother, 1997, 39(Suppl A):15-21.
  • 9Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans[J]. J Antimicrob Chemother, 1997, 39(Suppl.A): 129-138.
  • 10Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?[J] J Antimicrob Chemother 2000, 46: 347-350.

共引文献30

同被引文献17

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部